Marketing Authorisation for Project Quattro

RNS Number : 9005Z
Animalcare Group PLC
23 March 2012
 



23 March 2012

Animalcare Group plc

("Animalcare")

 

Marketing Authorisation for Project Quattro

 

Animalcare Group plc (AIM: ANCR), a leading supplier of veterinary medicines, announces that Project Quattro, a product from Animalcare's development pipeline, has received Marketing Authorisation from the Veterinary Medicines Directorate.

 

Receipt of Marketing Authorisation is a prerequisite for placing a new veterinary medicinal product on the market, after routine approvals for product packaging, allowing Animalcare to make final preparations for a full commercial launch.

 

For commercial reasons the full details of Project Quattro will be given at launch, with first sales expected to take place by the end of the current financial year (30 June 2012).

 

Stephen Wildridge, CEO of Animalcare Group plc, said: "The continued growth of our licensed veterinary medicines portfolio is an important aspect of our growth strategy. As we announced at our recent Interim Results, the trading in our core business is driven by new product introductions through the year and the news that the development of Project Quattro is advancing as planned is further testament to the delivery of our strategy."

 

For further information, please contact:

Animalcare Group plc

 

Stephen Wildridge (Chief Executive Officer)

Tel: 01904 487 601

 

 

N+1 Brewin (Nominated Advisor & Broker)

 

Aubrey Powell / Richard Lindley

Tel: 020 3201 3155 / 0113 241 0126

 

 

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

07980 541 893 or paul.mcmanus@walbrookpr.com

Helen Westaway

07841 917 679 or helen.westaway@walbrookpr.com

 

 

 

About Animalcare plc - www.animalcaregroup.co.uk

 

Animalcare Group develops and sells goods and services to veterinary professionals principally for use in companion animals.  It operates directly in the UK and through distribution and development partners in key markets in Western Europe.

 

Its principal product lines are licensed veterinary medicines and companion animal identification products and services.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEMFIEFESEFD
UK 100

Latest directors dealings